ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

CNTA Centessa Pharmaceuticals PLC

8.75
0.15 (1.74%)
23 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Centessa Pharmaceuticals PLC CNTA 나스닥 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.15 1.74% 8.75 09:00:00
개장가 저가 고가 종가 전일 종가
8.55 8.55 9.00 8.75 8.60
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
21/05/202421:45GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
14/05/202405:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/05/202405:23EDGAR2Form 8-K - Current report
14/05/202405:10GLOBECentessa Pharmaceuticals Reports Financial Results and..
09/05/202421:01EDGAR2Form ARS - Annual Report to Security Holders
09/05/202421:00EDGAR2Form DEF 14A - Other definitive proxy statements
24/04/202410:36GLOBECentessa Pharmaceuticals Announces Pricing of $100 Million..
24/04/202405:17GLOBECentessa Pharmaceuticals Announces $100 Million Proposed..
22/04/202420:00GLOBECentessa Pharmaceuticals Announces Open IND for ORX750;..
29/03/202405:28GLOBECentessa Pharmaceuticals Reports Business Highlights and..
22/02/202422:00GLOBECentessa Pharmaceuticals to Participate in TD Cowen’s 44th..
09/02/202421:12EDGAR2Form 8-K - Current report
09/02/202421:00GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
03/02/202407:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202407:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202407:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202407:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202407:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/02/202406:07EDGAR2Form 144 - Report of proposed sale of securities
22/01/202422:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
09/01/202421:56EDGAR2Form 8-K - Current report
03/01/202409:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202409:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202409:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202409:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202409:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:00GLOBECentessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P...
11/12/202321:05EDGAR2Form 8-K - Current report
11/12/202302:05GLOBECentessa Pharmaceuticals Announces New Data from an..
28/11/202306:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
14/11/202306:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202306:17EDGAR2Form 8-K - Current report
14/11/202306:05GLOBECentessa Pharmaceuticals Reports Financial Results and..
02/11/202322:09GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
31/10/202321:00GLOBECentessa Pharmaceuticals Announces Dosing of First Subject..
30/10/202321:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
25/10/202322:49EDGAR2Form 8-K - Current report
25/10/202321:00GLOBECentessa Pharmaceuticals Announces Preclinical Data..
04/10/202306:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202305:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202305:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202305:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202305:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202321:00GLOBECentessa Pharmaceuticals Announces Additions to Senior..
23/09/202305:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/09/202305:02EDGAR2Form 144 - Report of proposed sale of securities
02/09/202305:31EDGAR2Form 144 - Report of proposed sale of securities
31/08/202321:00GLOBECentessa Pharmaceuticals to Participate in the Morgan..
24/08/202306:08GLOBECentessa Pharmaceuticals to Present Preclinical Data for..
14/08/202320:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]